A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2002
12/17/2002	US6495604 Cycloalkene derivatives, process for producing the same, and use
12/17/2002	US6495599 Nutrients, nervous system development
12/17/2002	US6495587 Tricyclic indole-2-carboxylic acid compound used as NMDA receptor antagonist
12/17/2002	US6495584 Use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration
12/17/2002	US6495582 Erk (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
12/17/2002	US6495571 Administering to the mammal an effective cancer treatment amount of the compound 3,5-dichloro-4,6-diethoxy-2-(trichloromethyl)pyridine or and acid addition salt to treat the cancer
12/17/2002	US6495566 Potent antagonists at the strychnine insensitive glycine binding site associated with the n-methylaspartic acid receptor complex
12/17/2002	US6495565 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition
12/17/2002	US6495564 Such as 3-(6-((4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl)-1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)-benzaldehyde o-methyl-oxime; inhibiting abnormal cell growth
12/17/2002	US6495561 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
12/17/2002	US6495559 For therapy of obesity
12/17/2002	US6495555 Tricyclic Δ-3-piperidines as α2-antagonists
12/17/2002	US6495552 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid.
12/17/2002	US6495544 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase
12/17/2002	US6495543 Treating or preventing melatoninergic disorders
12/17/2002	US6495542 Such as 2-methoxy-n-(2-methyl-1h-benzimidazol-4-yl)-4-(2,3,4,5-tetrahydro-5-oxo-1h-1-benzazepin-1-yl)carbonyl-benzam ide; hypertension, heart failure, renal insufficiency, edema, ascites, vasopressin parasecretion syndrome
12/17/2002	US6495541 Tricyclic inhibitors of poly(ADP-ribose) polymerases
12/17/2002	US6495540 Lactams as inhibitors of A-β protein production
12/17/2002	US6495535 Prefilled syringes or ampules for self administration containing dissolved carbon dioxide or nitrogen to retard oxidative degradation
12/17/2002	US6495526 Inhibitors of cell-cycle progression and uses related thereto
12/17/2002	US6495525 N-((4-(((2-methylphenylamino)carbonyl)amino)phenyl)acetyl)-l -prolyl-3-methyl)-beta-alanine; very late antigen-4 cell adhesion inhibitor; inflammation and immune reactions
12/17/2002	US6495523 Anticonvulsants; stroke, head trauma, spinal injury, non-fatal cardiac arrest, surgery
12/17/2002	US6495522 Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
12/17/2002	US6495519 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
12/17/2002	US6495517 Cyclooxygenase inhibitor
12/17/2002	US6495376 Phosphoserine and phosphothreonine binding modules. the ww-domain containing polypeptides of the invention can be used, for example, to regulate cell growth; to treat neurodegenerative diseases; to screen for substances that
12/17/2002	US6495346 Do not react with foreign partners; amino acids inserted into proteins which naturally form dimers, mutated proteins only form complexes with themselves (homodimers) or with the mutated partner (heterodimers), not with nonmutated starting
12/17/2002	US6495172 Method of using steam ironing of fabrics as a way of causing reduction of physiological and/or subjective reactivity to stress in humans
12/17/2002	US6495166 Microencapsulation of risperidones or bupivacaine using glycolic acid-lactic acid copolymers and solvent emulsions to form sustained or time-release agents
12/17/2002	US6495164 Preparation of injectable suspensions having improved injectability
12/17/2002	US6495155 Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances
12/17/2002	US6495142 Administering a composition comprising a specified low-molecular weight chitosan and/or a derivative
12/17/2002	CA2260311C Remedy for cag repeat expansion diseases
12/17/2002	CA2246560C Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy
12/17/2002	CA2214439C A novel growth factor and a genetic sequence encoding same
12/17/2002	CA2153340C Application of riluzole in the treatment of parkinson's desease and parkinsonian syndromes
12/17/2002	CA2095223C Topical compositions for transdermal delivery of prodrug derivatives of morphine
12/17/2002	CA2053826C Pharmaceutical compositions active in the therapy of neurological affections in aids patients
12/14/2002	CA2390686A1 Cofactor-based screening method for nuclear receptor modulators and related modulators
12/13/2002	WO2001096575A1 Ceramide kinase and dna encoding the same
12/13/2002	CA2412876A1 Ceramide kinase and dna encoding the same
12/12/2002	WO2002099118A2 Method of identifying a polymorphism in cyp2d6
12/12/2002	WO2002099115A2 Nucleic acid-associated proteins
12/12/2002	WO2002099102A1 Numb protein expression inhibitors by musashi
12/12/2002	WO2002099087A2 Cell populations for detecting neuronal targets and potential active ingredients
12/12/2002	WO2002099036A2 Inhibition of neurodegeneration
12/12/2002	WO2002098907A2 Cation conducting gabaa receptors and their use
12/12/2002	WO2002098885A1 Modified psma ligands and uses related thereto
12/12/2002	WO2002098880A1 5-ethyl-imidazotriazinones
12/12/2002	WO2002098878A1 Trifluoromethylpurines as phosphodiesterase 4 inhibitors
12/12/2002	WO2002098873A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002	WO2002098869A2 1,4-disubstituted benzo-fused cycloalkyl urea compounds
12/12/2002	WO2002098868A1 Epothilone derivatives
12/12/2002	WO2002098865A2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
12/12/2002	WO2002098864A1 Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
12/12/2002	WO2002098863A1 Fused imidazole derivative
12/12/2002	WO2002098857A1 New indole derivatives with 5-ht6 receptor affinity
12/12/2002	WO2002098851A1 Derivatives 0f n,s-substitutions n'-1 [(hetero)aryl] alkyl-n'-[hetero) aryl] methyl isothioureas, method for producing salts and bases thereof, physiologically active n,s-substitutions n'-1 [(hetero)aryl] alkyl-n'-[hetero) aryl] methyl isothioureas, a pharmaceutical composition and curing method
12/12/2002	WO2002098849A2 Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
12/12/2002	WO2002098847A1 Cycloalkenylsulfonamide derivatives
12/12/2002	WO2002098846A1 Sulfonamide derivatives
12/12/2002	WO2002098840A1 Carboxylic acid derivative and medicine comprising salt or ester of the same
12/12/2002	WO2002098482A2 System for osmotic delivery of pharmaceutically active agents
12/12/2002	WO2002098462A1 Remedies containing aldose reductase inhibitor as the active ingredient for demyelinating diseases or diseases associated with demyelination
12/12/2002	WO2002098437A1 Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof
12/12/2002	WO2002098428A1 Tetracyclic compounds as pde5-inhibitors
12/12/2002	WO2002098427A2 Sustained-release analgesic compounds
12/12/2002	WO2002098426A1 Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
12/12/2002	WO2002098422A1 Use of methylnaltrexone to treat immune suppression
12/12/2002	WO2002098418A1 Combination comprising a p-gp inhibitor and an anti-epileptic drug
12/12/2002	WO2002098392A1 Nsaid formulation comprising a granular composition and an extra-granular composition
12/12/2002	WO2002098391A2 Process for preparing granular compositions
12/12/2002	WO2002098367A2 Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity
12/12/2002	WO2002098363A2 NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
12/12/2002	WO2002098351A2 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2
12/12/2002	WO2002083879A3 Immunotherapy based on dendritic cells
12/12/2002	WO2002081414A3 Supercritical hydrogenation
12/12/2002	WO2002076977A3 Rho-kinase inhibitors
12/12/2002	WO2002076976A3 Rho-kinase inhibitors
12/12/2002	WO2002072548A3 Heterocyclic compounds and their use as histamine h4 ligands.
12/12/2002	WO2002069946A3 Use of triazole compounds for prophylaxis and in therapy for neurodegenerative illnesses, brain traumas and cerebral ischaemia
12/12/2002	WO2002068015A9 Modular infusion device and method
12/12/2002	WO2002066458A3 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry
12/12/2002	WO2002064543A3 Novel succinate salt of o-desmethyl-venlafaxine
12/12/2002	WO2002062967A3 Multipotent o-2a progenitors from the neurohypophysis
12/12/2002	WO2002062792A9 Jnk inhibitor
12/12/2002	WO2002061052A3 An improved in vitro method of culturing mammalian cells for autologous cell implantation/transplantation methods
12/12/2002	WO2002059612A3 Animal model and cell-line expressing modified chlorine channel
12/12/2002	WO2002058620A3 Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant
12/12/2002	WO2002057252A3 Heterocyclic sulfonamide inhibitors of beta amyloid production
12/12/2002	WO2002056870A3 Method for treating sleep disorders
12/12/2002	WO2002056869A3 Method for treating sexual disorders
12/12/2002	WO2002056868A3 Method for treating stress or tension
12/12/2002	WO2002053169A3 Use of dipeptylpeptidase iv and aminopeptidase-n inhibitors in the treatment of ischaemia-induced neuro-degeneration
12/12/2002	WO2002046404A3 Schizophrenia-related voltage-gated ion channel gene and protein
12/12/2002	WO2002029408A3 Methods for diagnosing and treating huntington's disease
12/12/2002	WO2002029044A3 Modulation of the transcription of pro-inflammatory gene products
12/12/2002	WO2002026941A3 Primitive neural stem cells and method for differentiation of stem cells to neural cells
12/12/2002	WO2002018593A3 Modulation of fas and fasl expression
12/12/2002	WO2002018434A3 Proteins related to schizophrenia and uses thereof

1 ... 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 ... 1833